EGFR and head and neck squamous cell carcinoma: In future studies, the therapeutic efficacy of RIT for EGFR expressing HNSCC tumors that are resistant or less responsive to cetuximab or the combination therapeutic effect with cisplatin will be investigated in various HNSCC xenograft models.